GlassScriptPhysician profile
John A Petery
NPI 1811946965
$2,681.54
in general payments reported to CMS, 2019-2025
24 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical Primary Podiatric Medicine provider received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $295 · 2021: $266 · 2022: $468 · 2023: $527 · 2024: $361 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $946.82 | 2020-2024 | Nuzyra |
| Horizon Therapeutics Plc | $572.02 | 2019-2023 | Krystexxa |
| Smith+Nephew, INC. | $219.81 | 2019-2025 | Oasis, Grafix Pl, Collagenase Santyl |
| Zyla Life Sciences, INC. | $162.97 | 2019 | |
| Organogenesis INC. | $93.55 | 2024-2025 | Apligraf |
| Vertex Pharmaceuticals Incorporated | $89.65 | 2025 | |
| Radius Health, INC. | $55.91 | 2022 | |
| Grt US Holding, INC. | $55.16 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $54.92 | 2022-2023 | Jublia |
| Ani Pharmaceuticals, INC. | $48.84 | 2024 | Purified Cortrophin Gel |
| Nabriva Therapeutics, Plc | $48.29 | 2021 | |
| Medimetriks Pharmaceuticals, INC. | $39.86 | 2019 | |
| Melinta Therapeutics, LLC | $36.73 | 2019 | |
| Nevro Corp. | $34.33 | 2022-2024 | Senza |
| Amgen INC. | $30.49 | 2025 | Krystexxa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Djo, LLC | $29.55 | 2019-2021 | |
| Zimmer Biomet Holdings, INC. | $25.86 | 2019-2020 | |
| Medtronic, INC. | $24.59 | 2023 | Intellis Adaptivestim |
| Triad Life Sciences INC. | $24.21 | 2022 | |
| Depuy Synthes Sales INC. | $23.57 | 2019 | |
| Averitas Pharma INC. | $22.17 | 2025 | Qutenza |
| Sebela Pharmaceuticals INC. | $17.65 | 2022 | |
| Merck Sharp & Dohme LLC | $13.03 | 2019 | |
| Sandoz INC. | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Petery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.